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Case report 
Emicizumab is a humanized monoclonal bispecific antibody that mimics the co-factorial activity of factor 
VIII (FVIII) by binding activated factors (F)IX and X.1 It can be used in patients with haemophilia A with or 
without inhibitors, because it is not recognized by anti-FVIII antibodies. Its use as prophylactic agent, 
administered subcutaneously once weekly in patients with haemophilia A and inhibitors aged > 12 years 
showed a significant reduction in bleeding frequency as compared with previous bypassing therapy.2,3 
Nevertheless breakthrough bleeds may occur during prophylaxis with emicizumab as well as peri-operative 
bleeding complications,4,5 and, in those cases, standard bypassing agents (i.e., recombinant activated factor 
VII, rFVIIa and activated prothrombin complex concentrate, aPCC) are still needed to control bleeding.  
Moreover, the lack of routine laboratory tests able to monitor in vivo the haemostatic efficacy as well as the 
prothrombotic potential of bypassing agents renders the clinical management utmost problematic. The use of 
thrombin generation assay (TGA) has been proposed to individually tailor bypassing therapy and/or to 
monitor the efficacy of such therapy in patients undergoing surgery but with non-univocal results.6,7 
Recently, Dargaud et al. proposed the use of TGA as a helpful tool to limit adverse events that may occur 
when emicizumab is used in association with other haemostatic drugs as in the occasion of treatment of 
breakthrough bleeds.4 In fact, in HAVEN 1 study (NCT02622321), thrombotic microangiopathy and 
thrombosis were reported in 5 patients who received multiple doses of aPCC >100 IU/kg for more than 24 
hours to treat breakthrough bleeds.2 Thus, during prophylaxis with emicizumab, it is recommended to avoid 
the association of multiple high doses of aPCC and to use the lowest therapeutic doses of both rFVIIa or 
aPCC when bypassing therapy is needed.  
Because the surgical setting represents a challenge in the management of patients with haemophilia and 
inhibitors due to the risk of peri-operative bleeding for which intensive by-passing therapy is often required, 
with unpredictable and sometimes suboptimal efficacy, we present here a major non-elective orthopaedic 
surgery performed in a patient enrolled in the HAVEN 1 study at our Institution, for whom we used TGA to 
monitor the haemostatic efficacy of rFVIIa in combination with emicizumab.8 
The patient was a 56-year old man with severe haemophilia A and high-responding anti-FVIII inhibitors 
since childhood (historical peak titer: 126 BU/mL). He was a severe bleeder who used aPCC, plasma-derived 
porcine FVIII and rFVIIa to treat bleeds during his life. He already underwent 2 major orthopaedic 
procedures in 2002 and 2012. The first was a femur fracture fixation managed with rFVIIa by continuous 
infusion (20 μg/kg/h) according to our local practice at that time9; the patient was then switched to repeated 
boluses (130 μg/kg every 2h) to control severe bleeding at the surgical site. The second was a total knee 
replacement initially managed with high-dose rFVIIa boluses (140-190 μg/kg every 2h) in order to prevent 
bleeding complications. However, severe blood loss (>1500 mL) and anaemia occurred, so that sequential 
bypassing therapy (alternate aPCC and rFVIIa every 6-8h) was given on the basis of preliminary evidences 
available at that time10. 
The patient required blood transfusions in both occasions (7 and 9 units of red blood cells, RBC, 
respectively). On the occasion of the second procedure, TGA (see below) was used to measure coagulation 
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activation ex-vivo after the administration of bypassing agents, both pre-operatively in a non-bleeding state 
(testing 2 different doses of rFVIIa and aPCC) and then during the peri-operative period, as previously 
reported.7   
In 2017, while on regular prophylaxis with emicizumab 1.5 mg/kg/week in the frame of the HAVEN 1 trial 
(NCT02622321),2 the patient required right hip replacement due to the displacement of the screws used to fix 
the femoral fracture. Based on our local practice and protocol recommendations2, we chose rFVIIa to 
manage surgery. This decision was taken considering the strong and persistent anamnestic response 
previously observed in this patient, so that we wanted to save the use of FVIII for potentially life- or limb-
threatening bleeds. No thromboprophylaxis was given. 
Anti-FVIII inhibitors were measured pre-operatively by chromogenic assay using bovine substrates 
(Chromogenix, Coamatic® Factor VIII, IL) and resulted 2 BU/mL. Cell blood count, D-dimer, fibrinogen, 
LDH, haptoglobin and blood film were monitored to rule out signs of consumption (Disseminated 
Intravascular Coagulation, DIC) or Thrombotic MicroAngiopathy (TMA). Thrombin generation assay 
(Thrombinoscope™, Thrombinoscope BV) was performed on platelet-rich (PRP) and platelet-poor plasma 
(PPP) using 1pM tissue factor and 1μM phospholipids (only in PPP) as previously described.7   
At time of surgery (Day 0), a pre-operative rFVIIa bolus of 98 mcg/kg was administered and repeated rFVIIa 
boluses of 82 mcg/kg were given every 3 hours afterwards. The procedure lasted 1.5 hours, was uneventful 
with an intraoperative blood loss of 650 mL as expected for the type of surgery. During Day 0 Hb level and 
platelet count dropped significantly (Table 1). Schistocytes were never detectable and haemolysis markers 
were always negative. On Day 1 a right thigh hematoma developed and Hb levels further dropped despite 
RBC transfusions. Facing this complication, in the presence of a low inhibitor titer, we chose to switch to 
FVIII as rescue treatment. Replacement with a plasma-derived (pd) FVIII concentrate was the preferred 
treatment strategy to control bleeding rather than intensifying rFVIIa dosing regimen, because we were 
concerned about the recent report of a thrombotic risk.2 FVIII treatment was started 36 hours after surgery by 
bolus injection (115 IU/kg) followed by continuous infusion at 3.3-4 IU/kg/h. FVIII levels were monitored 
daily by chromogenic assay using bovine substrates (see above) and maintained above 80 IU/dL until Day 7 
when FVIII decreased to 24 IU/dL despite increasing the infusion rate up to 6 IU/kg/h due to antibody 
anamnestic response (80 BU/mL). At that time, the hematoma was solved, and the patient switched back to 
rFVIIa 80 mcg/kg every 4, 6 and 8h de-escalating rFVIIa doses every 72 hours. Antifibrinolytic therapy was 
associated until discharge on Day 13. Platelet count progressively improved during FVIII treatment and was 
normal when rFVIIa treatment had been restored (Table 1). 
Thrombin generation (TG) parameters were measured ex-vivo in this patient during standalone emicizumab 
prophylaxis at steady state and during hip replacement while on emicizumab plus rFVIIa. At the previous 
assessments done in 2012 on the occasion of the knee replacement, there was no clear dose-response 
relationship between TG parameters and rFVIIa administered in a non-bleeding state, and all values were 
well below the normal range.7 Endogenous thrombin potential (ETP) improved approaching normal values 
during rFVIIa treatment on peri-operative Day 0-1, when severe bleeding occurred.7 During emicizumab 
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prophylaxis at steady state ETP reached the lower limit of the normal range (1484 nM*min; range: 1306-
3099) but the thrombin peak was low (100 nM; range: 147-435). ETP and peak values further increased 
during rFVIIa treatment on the occasion of hip surgery (1583 nM*min and 160 nM, respectively). However, 
despite those increased values, the patient experienced a bleeding complication.  
Figure 1 shows TG measured ex-vivo in this patient in 2012 and in 2017 during bypassing therapy with and 
without emicizumab. As recently reported by Dargaud et al4, we observed an improvement of TG values 
after the addition of by-passing therapy to emicizumab. However, at variance with the French report, we 
found no correlation between TG values and clinical conditions. Notice that in their case low-dose aPCC was 
associated with emicizumab to treat a breakthrough bleed, while we are reporting on rFVIIa treatment in the 
surgical setting, at a time when factors other than bypassing treatment influence the haemostatic system and 
thrombin generation. These complex interactions impact on global coagulation results provided by TGA, that 
cannot selectively measure the haemostatic efficacy of therapeutic agents and their specific effect on clinical 
outcome. Indeed, TGA results in our surgical case treated with rFVIIa in association with emicizumab were 
not able to predict the occurrence of bleeding complication. The low-dose rFVIIa regimen was used with no 
the occurrence of thrombotic microangiopathy nor of thrombosis, but it was not sufficient to prevent 
bleeding. Hence, in the presence of an actually low titer inhibitor, FVIII replacement was feasible and was 
confirmed to be the most effective haemostatic therapy.    
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Table 1. Laboratory parameters and treatment regimen for hip replacement in an inhibitor patient on 
emicizumab 
 Hb  
(g/dL) 
Platelet 
count 
(x103/mmc) 
LDH 
(IU/mL) 
Fibrinogen 
(mg/dL) 
D-dimer 
(ng/mL) 
Haemostatic 
treatment 
RBC  
Day 0 (pre-op) 12.7 138 245 256 579 rFVIIa - 
Day 0 (6 h post-op) 7.9 108 na na na rFVIIa 3 Units 
Day 1 (morning) 6.6 64 111 155 887 rFVIIa 2 Units 
Day 1 (afternoon) 10.3 84 189 251 1055 pdFVIII - 
Days 2-7 8.9-
10.6 
80-142 na 348 707 pdFVIII 3 Units 
Days 8-13 8.7-9.8 182-322 363-391 541-781 1302-2634 rFVIIa + 
tranexamic acid* 
2 Units 
Day 0: day of surgery; pre-op: pre-operatively; post-op: post-operatively; Hb: haemoglobin; na: not 
available; pdFVIII: plasmaderived FVIII; RBC: red blood cells 
Normal range is 135-225 IU/mL for LDH, 165-350 mg/dL for fibrinogen and < 230 ng/mL for D-dimer 
*10 mg/kg body weight intravenously once daily 
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Figure 1. Thrombin generation measured in a patient with haemophilia A and inhibitors treated with 
rFVIIa before and after emicizumab prophylaxis.  
Thrombin generation measured ex-vivo in platelet-rich (panel A) and platelet-poor (B) plasma in the patient 
at baseline without any treatment (continuous light blue line), during emicizumab prophylaxis at steady state 
(green square), 30’ post 90 mcg/kg rFVIIa in a non-bleeding state before starting emicizumab prophylaxis 
(pink triangle), 30’ post 190 mcg/kg rFVIIa as pre-operative bolus before starting emicizumab prophylaxis 
(yellow circle), 30’ post 98 mcg/kg rFVIIa as pre-operative bolus during emicizumab prophylaxis (red 
diamond) and 30’ post 80 mcg/kg rFVIIa during emicizumab prophylaxis on post-surgical Day 1 during 
active bleeding (dark blue circle; measured only in PPP because PRP could not be obtained due to 
thrombocytopenia). The black continuous line depicts values of a normal control. 
The horizontal red bars depict the lower limit of the normal range for thrombin peak measured in PRP (78 
nM; panel A) and PPP (147 nM; panel B). The higher limits were both out of scale (421 nM in PRP and 435 
nM in PPP, respectively).   
 
 

